Literature DB >> 2644876

Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon.

O Codella1, P Caramaschi, O Olivieri, L Perbellini, A Perbellini, L M Bambara, R Corrocher, G De Sandre.   

Abstract

Twenty-eight patients suffering from either primary or secondary Raynaud's phenomenon were treated with nifedipine and ketanserin. Each patient was treated with one of the two drugs administered after an adequate washout period. Furthermore each patient was submitted before and after treatment with each drug to computerized digital thermometry to evaluate the therapeutic response. The data obtained during the intake of the two drugs at zero, five, and twenty-three minutes were compared with thermometry-relevant baseline data at the same periods. Ketanserin proved to be useful in the treatment of Raynaud's phenomenon and statistically significantly superior (alpha less than 0.05) with respect to nifedipine in the thermometric controls and also in the subjective evaluation of the patients (p less than 0.02). In this study nifedipine did not show particular efficacy. Furthermore only 2 patients had to discontinue treatment with ketanserin, whereas 8 had to discontinue treatment with nifedipine (p less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2644876     DOI: 10.1177/000331978904000206

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  6 in total

Review 1.  Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis.

Authors:  J Pope; D Fenlon; A Thompson; B Shea; D Furst; G Wells; A Silman
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 2.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

3.  Finger skin temperature in patients affected by Raynaud's phenomenon with or without anticentromere antibody positivity.

Authors:  P Caramaschi; D Biasi; A Carletto; T Manzo; M Randon; S Zeminian; L M Bambara
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

Review 4.  The role of serotonin in cardiovascular diseases and their treatment.

Authors:  P A van Zwieten; G J Blauw; P van Brummelen
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

Review 5.  Oral vasodilators for primary Raynaud's phenomenon.

Authors:  Marlene Stewart; Joanne R Morling
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 6.  Calcium channel blockers for primary Raynaud's phenomenon.

Authors:  Holly Ennis; Michael Hughes; Marina E Anderson; Jack Wilkinson; Ariane L Herrick
Journal:  Cochrane Database Syst Rev       Date:  2016-02-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.